Korro Bio, Inc. (KRRO) stock
KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
$14.31−0.10 (-0.69%)
Close on Nov 12, 2026Market cap $210.72MP/E –Yield –
Korro Bio operating margin
Operating margin is operating income as a percentage of revenue.
Korro Bio's operating margin for the twelve months ending Sep 30, 2026 was -8467.3%. For fiscal 2025 it was -1906.4%, against -4047.1% the year before. The highest annual figure on record is -71.4% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1906.4% | +2140.7 |
| FY2024 | Dec 31, 2024 | -4047.1% | −3449.8 |
| FY2021 | Dec 31, 2021 | -597.3% | −522.8 |
| FY2020 | Dec 31, 2020 | -74.5% | −3.1 |
| FY2019 | Dec 31, 2019 | -71.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -3900.6% | −2886.1 |
| Q3 FY2025 | Sep 30, 2025 | -1764.9% | −1579.2 |
| Q2 FY2025 | Jun 30, 2025 | -1863.2% | −1428.9 |
| Q1 FY2025 | Mar 31, 2025 | -981.2% | −877.9 |
| Q4 FY2024 | Dec 31, 2024 | -1014.5% | −966.4 |
| Q2 FY2021 | Jun 30, 2021 | -185.7% | −112.9 |
| Q1 FY2021 | Mar 31, 2021 | -434.3% | −356.4 |
| Q4 FY2020 | Dec 31, 2020 | -103.3% | +34.5 |
| Q3 FY2020 | Sep 30, 2020 | -48.2% | −43.0 |
| Q2 FY2020 | Jun 30, 2020 | -72.7% | – |
| Q1 FY2020 | Mar 31, 2020 | -77.8% | – |
| Q4 FY2019 | Dec 31, 2019 | -137.8% | – |
| Q3 FY2019 | Sep 30, 2019 | -5.2% | – |
See a number that looks wrong?